[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
BACKGROUND
The standard therapy for gastric cancer with peritoneal metastasis has remained unclear.


OBJECTIVE
This prospective feasibility study was aimed to investigate the efficacy and safety of S-1 plus paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis able to take oral feeding.


METHODS
Seven patients were enrolled in this study. Paclitaxel 50mg/m2 was administered on days 1 and 8. S-1 was administered orally at 40 mg/m2 bid for 14 consecutive days, followed by a 1-week rest. Overall survival, the response rate and safety were examined for efficacy and tolerability.


RESULTS
The median survival time was 310 days. The response rate in five patients was 80. 0%. Grade 3 toxicity was observed in two patients. Combination chemotherapy of weekly paclitaxel and S-1 demonstrated efficacy and tolerable toxicity. This regimen will be one of the initial treatment options for unresectable or metastatic gastric cancer with peritoneal metastasis.
Kimura
Yutaka
Y
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG), NTT West Osaka Hospital, Japan.
Machida
Hirohisa
H
Fujitani
Kazumasa
K
Yamamoto
Moritoshi
M
Tominaga
Kazunari
K
Yano
Hiroshi
H
Shimokawa
Toshio
T
Takiuchi
Hiroya
H
Tsujinaka
Toshimasa
T
Furukawa
Hiroshi
H
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel